These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28714868)

  • 1. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
    J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
    Archin NM; Bateson R; Tripathy MK; Crooks AM; Yang KH; Dahl NP; Kearney MF; Anderson EM; Coffin JM; Strain MC; Richman DD; Robertson KR; Kashuba AD; Bosch RJ; Hazuda DJ; Kuruc JD; Eron JJ; Margolis DM
    J Infect Dis; 2014 Sep; 210(5):728-35. PubMed ID: 24620025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
    Gay CL; Kuruc JD; Falcinelli SD; Warren JA; Reifeis SA; Kirchherr JL; James KS; Dewey MG; Helms A; Allard B; Stuelke E; Gamble A; Plachco A; Gorelick RJ; Eron JJ; Hudgens M; Garrido C; Goonetilleke N; DeBenedette MA; Tcherepanova IY; Nicolette CA; Archin NM; Margolis DM
    Sci Rep; 2020 Mar; 10(1):5134. PubMed ID: 32198428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.
    Ling L; Kim M; Soper A; Kovarova M; Spagnuolo RA; Begum N; Kirchherr J; Archin N; Battaglia D; Cleveland D; Wahl A; Margolis DM; Browne EP; Garcia JV
    mBio; 2024 Sep; 15(9):e0163224. PubMed ID: 39136440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
    Gay CL; Hanley PJ; Falcinelli SD; Kuruc JD; Pedersen SM; Kirchherr J; Raines SLM; Motta CM; Lazarski C; Chansky P; Tanna J; Shibli A; Datar A; McCann CD; Sili U; Ke R; Eron JJ; Archin N; Goonetilleke N; Bollard CM; Margolis DM
    J Infect Dis; 2024 Mar; 229(3):743-752. PubMed ID: 38349333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    Garrido C; Tolstrup M; Søgaard OS; Rasmussen TA; Allard B; Soriano-Sarabia N; Archin NM; Margolis DM
    AIDS; 2019 Mar; 33(4):605-613. PubMed ID: 30830886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
    Sung JA; Sholtis K; Kirchherr J; Kuruc JD; Gay CL; Nordstrom JL; Bollard CM; Archin NM; Margolis DM
    EBioMedicine; 2017 Sep; 23():52-58. PubMed ID: 28803740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.